AwardMay 12, 2026, 07:36 AM
Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X
AI Summary
Incannex Healthcare Inc. announced it won the "Best New Technology Solution for Drug Development" award at the 10th annual MedTech Breakthrough Awards. This recognition highlights the company's lead drug candidate, IHL-42X, an oral fixed-dose combination therapy for obstructive sleep apnea (OSA). The award validates the strong clinical progress of IHL-42X, which demonstrated statistically significant and clinically meaningful reductions in AHI, alongside improvements in oxygenation, sleep quality, and patient-reported fatigue in its Phase 2 RePOSA clinical trial.
Key Highlights
- Incannex Healthcare won the "Best New Technology Solution for Drug Development" award.
- The award recognizes IHL-42X, an oral fixed-dose combination therapy for obstructive sleep apnea (OSA).
- IHL-42X combines dronabinol and acetazolamide, targeting physiological drivers of OSA.
- Phase 2 RePOSA trial showed significant reductions in apnea-hypopnea index (AHI).
- Trial also demonstrated improvements in oxygenation, sleep quality, and fatigue outcomes.
- The award validates the company's progress and leadership in next-generation drug development.
Price Impact
More from IXHL